Radium of radium Curie used the residues after extraction of uranium from pitchblende. The uranium had been extracted by dissolution in sulfuric acid leaving radium sulfate, which is similar to barium sulfate but even less soluble in the residues. The residues also contained rather substantial amounts of barium sulfate which thus acted as a carrier for the radium sulfate. The first steps of the radium extraction process involved boiling with sodium hydroxide followed by hydrochloric acid treatment to remove as much as possible of other compounds. The remaining residue was then treated with sodium carbonate to convert the barium sulfate into
Radium-223 kBq/ml), sodium chloride, and other ingredients for intravenous injection. Algeta ASA was later acquired by Bayer who is now the sole owner of Xofigo. The recommended regimen is six treatments of 55 kBq/kg (1.3 uCi per kg), repeated at 4-week intervals. The use of radium-223 to treat metastatic bone cancer relies on the ability of alpha radiation from radium-223 and its short-lived decay products to kill cancer cells. Radium is preferentially absorbed by bone by virtue of its chemical similarity to calcium, with most radium-223 that is not taken up by the bone being cleared, primarily via the gut, and